Cardiovascular profile of loratadine |
| |
| Authors: | J. A. Hey,M. Affrime,B. Cobert,W. Kreutner,& F. M. Cuss |
| |
| Affiliation: | Schering-Plough Research Institute, Kenilworth, New Jersey, USA |
| |
| Abstract: | The extremely low reporting rate of cardiovascular adverse events for loratadine, the possible preferential use of loratadine in patients with pre-existing cardiovascular disorders, and the impressive lack of cardiovascular effects at extremely high concentrations in clinical and preclinical studies demonstrate the very safe cardiovascular profile of loratadine. |
| |
| Keywords: | loratadine non-sedating antihistamine cardiovascular |
|
|
